Seguir
Nedime Serakinci
Nedime Serakinci
Professor of Medical Genetics & Biology, Cyprus international University
Dirección de correo verificada de ciu.edu.tr
Título
Citado por
Citado por
Año
Telomerase expression extends the proliferative life-span and maintains the osteogenic potential of human bone marrow stromal cells
JL Simonsen, C Rosada, N Serakinci, J Justesen, K Stenderup, ...
Nature biotechnology 20 (6), 592-596, 2002
10022002
Adult human mesenchymal stem cell as a target for neoplastic transformation
N Serakinci, P Guldberg, JS Burns, B Abdallah, H Schrødder, T Jensen, ...
Oncogene 23 (29), 5095-5098, 2004
4972004
The ocean sampling day consortium
A Kopf, M Bicak, R Kottmann, J Schnetzer, I Kostadinov, K Lehmann, ...
Gigascience 4, 1-5, 2015
2202015
Primary culture
RI Freshney
Culture of animal cells: a manual of basic technique, 2005
118*2005
Therapeutic potential of adult stem cells
N Serakinci, WN Keith
European journal of cancer 42 (9), 1243-1246, 2006
1042006
A gene expression signature classifying telomerase and ALT immortalization reveals an hTERT regulatory network and suggests a mesenchymal stem cell origin for ALT
K Lafferty-Whyte, CJ Cairney, MB Will, N Serakinci, MG Daidone, ...
Oncogene 28 (43), 3765-3774, 2009
1012009
Telomere stability and telomerase in mesenchymal stem cells
N Serakinci, J Graakjaer, S Kolvraa
Biochimie 90 (1), 33-40, 2008
952008
The role of human papillomaviruses in cancer progression
P Tulay, N Serakinci
Journal of Cancer Metastasis and Treatment 2, 201-213, 2016
852016
Mesenchymal stem cells, cancer challenges and new directions
N Serakinci, U Fahrioglu, R Christensen
European Journal of Cancer 50 (8), 1522-1530, 2014
762014
Ectopically hTERT expressing adult human mesenchymal stem cells are less radiosensitive than their telomerase negative counterpart
N Serakinci, R Christensen, J Graakjaer, CJ Cairney, WN Keith, J Alsner, ...
Experimental cell research 313 (5), 1056-1067, 2007
732007
Telomerase promoter reprogramming and interaction with general transcription factors in the human mesenchymal stem cell
N Serakinci, SF Hoare, M Kassem, SP Atkinson, WN Keith
Regenerative Medicine 1 (1), 125-131, 2006
712006
Role of melatonin in the treatment of COVID-19; as an adjuvant through cluster differentiation 147 (CD147)
AO Sehirli, S Sayiner, N Serakinci
Molecular biology reports 47 (10), 8229-8233, 2020
612020
Association of leptin receptor gene Q223R polymorphism on lipid profiles in comparison study between obese and non-obese subjects
E Becer, G Mehmetçik, H Bareke, N Serakıncı
Gene 529 (1), 16-20, 2013
532013
Transformation of human mesenchymal stem cells in radiation carcinogenesis: long-term effect of ionizing radiation
R Christensen, J Alsner, F Brandt Sorensen, F Dagnaes-Hansen, ...
Regenerative medicine 3 (6), 849-861, 2008
482008
A mutation in a functional Sp1 binding site of the telomerase RNA gene (hTERC) promoter in a patient with Paroxysmal Nocturnal Haemoglobinuria
WN Keith, T Vulliamy, J Zhao, C Ar, C Erzik, A Bilsland, B Ulku, A Marrone, ...
BMC Hematology 4, 1-8, 2004
482004
Mesenchymal stem cells as therapeutic delivery vehicles targeting tumor stroma
N Serakinci, R Christensen, U Fahrioglu, FB Sorensen, ...
Cancer Biotherapy and Radiopharmaceuticals 26 (6), 767-773, 2011
472011
Detection and sizing of telomeric repeat DNA in situ
N Serakinci, J Koch
Nature Biotechnology 17 (2), 200-201, 1999
391999
Telomere dynamics in human mesenchymal stem cells after exposure to acute oxidative stress
M Harbo, S Koelvraa, N Serakinci, L Bendix
DNA repair 11 (9), 774-779, 2012
372012
Impact of circadian disruption on health; SIRT1 and Telomeres
M Osum, N Serakinci
DNA repair 96, 102993, 2020
342020
A solid ultra fine self-nanoemulsifying drug delivery system (S-SNEDDS) of deferasirox for improved solubility: optimization, characterization, and in vitro cytotoxicity studies
A Alghananim, Y Özalp, B Mesut, N Serakinci, Y Özsoy, S Güngör
Pharmaceuticals 13 (8), 162, 2020
332020
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20